Antibody clues could predict kidney transplant outcomes
NCT ID NCT07374484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how levels of a specific antibody (AT1R-Ab) change before and after kidney transplantation in 241 patients. Researchers monitored these antibodies over one year to see if they relate to kidney function and graft survival. The goal is to find better ways to predict transplant success and improve decision-making for doctors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could help doctors better predict kidney transplant success and personalize care for recipients.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to all transplant patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOTENSIN II TYPE 1 RECEPTOR ANTIBODY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Seoul National University Hospital
Seoul, Seoul, 03080, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI may spot hidden kidney transplant rejection
- A drug given to organ donors may help kidneys work faster after transplant
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection
- Smartphone app and booklet could help kidney transplant patients stick to medications